



ConjuChem Biotechnologies Inc.  
225, President-Kennedy Avenue  
Third Floor, Suite 3950  
Montréal, Québec H2X 3Y8  
Canada

---

For immediate release

## CONJUCHEM BIOTECHNOLOGIES ANNOUNCES FILING OF PATENT REEXAMINATION REQUEST IN U.S. PATENT & TRADEMARK OFFICE

**MONTREAL, July 9, 2007** – ConjuChem Biotechnologies Inc. (TSX:CJB) announced today that it has submitted an *inter partes* request to the U.S. Patent & Trademark Office for reexamination of Patent No. 6,924,264. The patent, entitled “Modified Exendins and Exendin Agonists”, was issued in August 2005 and is assigned to Amylin Pharmaceuticals, Inc. ConjuChem Biotechnologies is requesting a reexamination of a number of claims in the patent as being invalid due to obviousness and/or lack of novelty. This action is being taken in the U.S. Patent & Trademark Office. No counterpart to Patent No. 6,924,264 has issued in Europe.

ConjuChem Biotechnologies has a number of issued patents in the insulinotropic peptide field including a composition of matter patent for PC-DAC™:Exendin-4 (Patent No. 6,593,295) which was issued by the U.S. Patent & Trademark Office in July 2003. The reexamination request to the U.S. Patent & Trademark Office does not involve any of ConjuChem Biotechnologies’ patents.

ConjuChem Biotechnologies also confirmed that ongoing discussions with other companies regarding the possible licensing of its PC-DAC™:Exendin-4 program are expected to continue and that such parties are supportive of the request for reexamination. ConjuChem Biotechnologies will provide a further update on its business development activities with the filing of its third quarter financial statements in September.

### **About PC-DAC™:Exendin-4**

Exendin-4, like Glucagon-like peptide-1 (GLP-1), is an insulinotropic peptide and an agonist for the GLP-1 receptor. Exendin-4 decreases glucagon and increases insulin secretion in a glucose-dependent manner. Exendin-4 may stimulate  $\beta$ -cell proliferation, restore  $\beta$ -cell sensitivity to glucose, delay gastric emptying, and increase peripheral sensitivity to glucose. The clinical utility of Exendin-4 is somewhat limited by its relatively short half-life in plasma. Developed with ConjuChem’s proprietary PC-DAC™ technology, PC-DAC™:Exendin-4 is a modified Exendin-4 analogue that is covalently bound to recombinant human albumin (**Recombunin**®, provided by Novozymes Delta Limited). Data from Phase I/II clinical studies have demonstrated that the preformed albumin-peptide conjugate has a much longer half-life than the peptide alone. The product is a highly soluble liquid formulation that is injectable in a small volume with a small gauge needle.



### **About ConjuChem Biotechnologies**

ConjuChem Biotechnologies, developer of next generation medicines from therapeutic peptides, is creating long-acting compounds based on bioconjugation platform technologies. When applied to peptides, the Company's systemic DAC<sup>TM</sup> and PC-DAC<sup>TM</sup> Technologies enable the creation of new drugs with significantly enhanced therapeutic properties as compared to the original peptide. Detailed descriptions of the Company can be viewed on the Company's website [www.conjuchem.com](http://www.conjuchem.com).

### **Forward-Looking Statements**

Some of the statements made herein may constitute forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause ConjuChem Biotechnologies' actual results, performance or achievements to be materially different from those expressed or implied by any of the Company's statements. Actual events or results may differ materially. We disclaim any intention, and assume no obligation, to update these forward-looking statements.

### **For more information, please contact:**

Mark Perrin  
President & CEO  
ConjuChem Biotechnologies Inc.  
514-844-5558, ext. 311  
perrin@conjuchem.com

Lennie Ryer, CA  
Vice President, Finance & CFO  
ConjuChem Biotechnologies Inc.  
514-844-5558, ext. 224  
ryer@conjuchem.com